Elena Zamagni, MD, PhD, of the University of Bologna, Bologna, Italy, discusses the benefit of PET/CT in combination with bone marrow analysis as a measure of minimal residual disease (MRD) in newly diagnosed transplant-eligible multiple myeloma (MM) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).